Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP,30 mg/30 mL (1 mg/mL) Multiple-Dose Vial".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has informed the exchange about a press release regarding its US subsidiary launching Epinephrine Injection USP (30 mg/30 mL, 1 mg/mL) in a Multiple-Dose Vial format in the United States. Epinephrine is a widely used emergency medication for severe allergic reactions, cardiac arrest, and anaphylaxis. The product is being introduced through Glenmark Pharmaceuticals Inc., USA. This adds to Glenmark's injectable portfolio in the US generic injectables market. The launch expands the company's presence in the critical care injectables segment.
This is a routine product launch that strengthens Glenmark's US generics portfolio but is unlikely to be a major stock-moving event on its own. It signals continued investment in the US market, which remains a key revenue driver for the company.